June 24, 2026 EQT Life Sciences joins new investors Frazier Life Sciences, Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation, in RQ Bio's oversubscribed USD 115 million Series A financing RQ Bio is developing antibody therapies to prevent seasonal influenza in high-risk and immunocompromised populations, with the Series A supporting its clinical progression and broader infectious disease pipeline As

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H 2027 with upfront proceeds June 24, 2026 -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calciu

Tinostamustine is being studied in newly diagnosed glioblastoma patients who often face limited treatment options June 24, 2026 -- Knoa Pharma LLC ("Knoa Pharma"), a public health-focused pharmaceutical company, and the Global Coalition for Adaptive Research ("GCAR") announced that the first patient was randomized to the tinostamustine arm on GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in early April. In addition, the first patient in recurrent setting

June 24, 2026 -- REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6). Under the established framework, Stemchymal® will be manufactured by Taiwan-based Steminent

June 24, 2026 -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Centessa Pharmaceuticals plc. Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders. "The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss June 24, 2026 -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calci

Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart Eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, psychological well-being, and workplace productivity Late breaker bocunebart presentation will provide further insight into pituitary adenylate

LTX-002 is a first-in-class antisense oligonucleotide targeting SPTLC1, designed to restore lipid metabolism in the CNS, a novel approach with the potential to address both sporadic and genetic forms of ALS June 23, 2026 -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced that the first participant has been dosed in NeurALS, a Phase 1/2 trial of LTX-002 in adults with amyotrophic lateral sclerosis

June 23, 2026 -- Calico Life Sciences LLC (Calico), a clinical-stage biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) granted fosigotifator Breakthrough Therapy Designation (BTD) for the treatment of Vanishing White Matter (VWM) disease. Fosigotifator, an investigational eIF2B activator, is currently in a Phase 1b/2 clinical trial evaluating its safety, tolera

June 22, 2026 -- NanoGhost Ltd., a biotechnology company developing a proprietary targeted drug delivery platform for cancer and other severe diseases, announced today that it has been awarded a new grant from the Israel Innovation Authority to support an innovative collaborative research program with Ben-Gurion University of the Negev via its technology transfer company, BGN. This marks the sixth grant awarded to NanoGhost by the Israel Innovation Authority, reflecting continued confidence in